Engineered nucleic acids and methods of use thereof
First Claim
Patent Images
1. A pharmaceutical formulation comprising:
- i) an effective amount of a messenger ribonucleic acid (mRNA) sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO;
23; and
ii) a pharmaceutically acceptable carrier,wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof.
4 Assignments
0 Petitions
Accused Products
Abstract
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject'"'"'s heath or wellbeing.
1004 Citations
9 Claims
-
1. A pharmaceutical formulation comprising:
-
i) an effective amount of a messenger ribonucleic acid (mRNA) sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO;
23; andii) a pharmaceutically acceptable carrier, wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof. - View Dependent Claims (2, 3)
-
-
4. A pharmaceutical formulation comprising:
-
i) an effective amount of an mRNA sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO;
23;ii) a cell penetration agent; and iii) a pharmaceutically acceptable carrier, wherein the formulation is suitable for repeated intravenous administration to a mammalian subject in need thereof. - View Dependent Claims (5, 6)
-
- 7. An mRNA sequence encoding an insulin polypeptide, wherein the mRNA sequence is at least 95% identical to the sequence of SEQ ID NO:
Specification